About Hairy and enhancer of split-related protein HELT
Hairy and enhancer of split-related protein HELT (HELT) is a protein
from Homo sapiens identified by UniProt accession
A6NFD8, 242 residues long.
MolForge cross-references it against 0 known binders and
62 disease associations.
Target properties
| Protein name | Hairy and enhancer of split-related protein HELT |
|---|
| UniProt accession | A6NFD8 |
|---|
| Gene | HELT |
|---|
| Organism | Homo sapiens |
|---|
| Length | 242 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (62)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.31
- hypertension · score 0.28
- lesion of sciatic nerve · score 0.23
- neuritic plaque measurement · score 0.23
- essential hypertension · score 0.21
- mean platelet volume · score 0.18
- developmental and epileptic encephalopathy, 9 · score 0.05
- adolescent idiopathic scoliosis · score 0.05
- autosomal dominant epilepsy with auditory features · score 0.05
- cancer · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A6NFD8-F1 | alphafold | PREDICTED | 65.85 | — |
Amino-acid sequence (242 residues)
MSDKLKERKR TPVSHKVIEK RRRDRINRCL NELGKTVPMA LAKQSSGKLE KAEILEMTVQ YLRALHSADF PRGREKAELL AEFANYFHYG YHECMKNLVH YLTTVERMET KDTKYARILA FLQSKARLGA EPAFPPLGSL PEPDFSYQLH PAGPEFAGHS PGEAAVFPQG SGAGPFPWPP GAARSPALPY LPSAPVPLAS PAQQHSPFLT PVQGLDRHYL NLIGHAHPNA LNLHTPQHPP VL
Explore Hairy and enhancer of split-related protein HELT with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets